Pharmacological gastroprotection: Indications, possibilities and risks
Meditsinskiy sovet = Medical Council · 17.10.2025 · (15) · 74-84
DOI: 10.21518/ms2025-398 ↗Kurz gefasst
Fachartikel in der Zeitschrift Meditsinskiy sovet = Medical Council, online erschienen am 17.10.2025. Verfasst von S. Yu. Serebrova und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
The article is an analytical review of the concept of pharmacological gastroprotection. The authors emphasize that the integrity of the gastric mucosa is maintained due to a complex balance between the factors of aggression (hydrochloric acid, pepsin, NSAIDs, H. pylori ) and protection (mucus, bicarbonates, prostaglandins, adequate microcirculation, mucosal regeneration). The main mechanisms of damage to the gastric mucosa are listed and a classification of protective factors is given. The terms “cytoprotection” and “gastroprotection” are considered. It is substantiated that true gastroprotection is defined as a pharmacological enhancement of the protective properties of the mucosa, and not the suppression of acid aggression. In this regard, proton pump inhibitors (PPIs), which remain the “gold standard” for the prevention of dangerous complications (bleeding, perforation), do not belong to true gastroprotectors, since they act on the aggression factor. The criteria for assessing the risk of gastrointestinal bleeding and the approach to prescribing gastroprotectors are presented. The authors classify bismuth preparations, misoprostol and rebamipide as true drugs with proven gastroprotective properties. However, each of them has serious limitations: the risk of bismuth accumulation with long-term use, pronounced side effects of misoprostol (diarrhea, abortive effect) and an insufficiently strong evidence base for rebamipide for widespread use. The key problem of clinical practice is the low frequency of gastroprotection use even among high-risk patients (elderly age, taking anticoagulants and NSAIDs, ulcer history), for whom it is indicated first and foremost. The main conclusion of the work is that classical gastroprotection has given way to antisecretory therapy not because of inefficiency, but because of the simplicity, predictability and strong evidence base of PPIs in preventing life-threatening complications. A paradigm shift will require the development of a new drug with clear advantages over existing standard therapy.
Zitieren
APA
Serebrova, S. Y., Prokofiev, A. B., Esakova, E. Y., Zhuravleva, M. V., Eremenko, N. N., & Kazakov, R. E. (2025). Pharmacological gastroprotection: Indications, possibilities and risks. Meditsinskiy sovet = Medical Council, 74-84. https://doi.org/10.21518/ms2025-398
Vancouver
Serebrova SY, Prokofiev AB, Esakova EY, Zhuravleva MV, Eremenko NN, Kazakov RE. Pharmacological gastroprotection: Indications, possibilities and risks. Meditsinskiy sovet = Medical Council. 2025:74-84. doi:10.21518/ms2025-398
BibTeX
@article{Serebrova2025,
author = {Serebrova, S. Yu. and Prokofiev, A. B. and Esakova, E. Yu. and Zhuravleva, M. V. and Eremenko, N. N. and Kazakov, R. E.},
title = {Pharmacological gastroprotection: Indications, possibilities and risks},
journal = {Meditsinskiy sovet = Medical Council},
year = {2025},
number = {15},
pages = {74--84},
doi = {10.21518/ms2025-398}
}
EUVIMED